Nandita Khera

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi request reprint Financial burden in recipients of allogeneic hematopoietic cell transplantation
    Nandita Khera
    Division of Hematology Oncology, Mayo Clinic, Phoenix, Arizona Electronic address
    Biol Blood Marrow Transplant 20:1375-81. 2014
  2. pmc Costs of allogeneic hematopoietic cell transplantation using reduced intensity conditioning regimens
    Nandita Khera
    Division of Hematology Oncology, Mayo Clinic in Arizona, Phoenix, Arizona, USA Dana Farber Brigham and Women s Cancer Center, Boston, Massachusetts, USA Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    Oncologist 19:639-44. 2014
  3. pmc Costs of second allogeneic hematopoietic cell transplantation
    Nandita Khera
    Division of Hematology Oncology, Mayo Clinic in Arizona, Phoenix, AZ, USA
    Transplantation 96:108-15. 2013
  4. pmc Nonmalignant late effects and compromised functional status in survivors of hematopoietic cell transplantation
    Nandita Khera
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    J Clin Oncol 30:71-7. 2012
  5. ncbi request reprint Economics of hematopoietic cell transplantation
    Nandita Khera
    Division of Hematology Oncology, Mayo Clinic Arizona, Phoenix, AZ, USA
    Blood 120:1545-51. 2012
  6. pmc Influence of conventional cardiovascular risk factors and lifestyle characteristics on cardiovascular disease after hematopoietic cell transplantation
    Eric J Chow
    Eric J Chow, K Scott Baker, Stephanie J Lee, Mary E D Flowers, Kara L Cushing Haugen, Yoshihiro Inamoto, Wendy M Leisenring, Karen L Syrjala, and Paul J Martin, Fred Hutchinson Cancer Research Center Eric J Chow, K Scott Baker, Seattle Children s Hospital Eric J Chow, K Scott Baker, Stephanie J Lee, Mary E D Flowers, and Paul J Martin, University of Washington, Seattle, WA and Nandita Khera, Mayo Clinic, Phoenix, AZ
    J Clin Oncol 32:191-8. 2014
  7. pmc Clinical benefit of response in chronic graft-versus-host disease
    Yoshihiro Inamoto
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington Electronic address
    Biol Blood Marrow Transplant 18:1517-24. 2012
  8. ncbi request reprint Impact of Age on Quality of Life, Functional Status, and Survival in Patients with Chronic Graft-versus-Host Disease
    Areej El-Jawahri
    Division of Bone Marrow Transplantation, Massachusetts General Hospital Cancer Center, Boston, Massachusetts Harvard Medical School, Boston, Massachusetts Electronic address
    Biol Blood Marrow Transplant 20:1341-8. 2014
  9. ncbi request reprint Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte ant
    James L Slack
    Division of Hematology and Oncology, Mayo Clinic Arizona, Phoenix, AZ 85054, USA
    Biol Blood Marrow Transplant 19:1167-74. 2013
  10. pmc Validation of measurement scales in ocular graft-versus-host disease
    Yoshihiro Inamoto
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Ophthalmology 119:487-93. 2012

Collaborators

Detail Information

Publications12

  1. ncbi request reprint Financial burden in recipients of allogeneic hematopoietic cell transplantation
    Nandita Khera
    Division of Hematology Oncology, Mayo Clinic, Phoenix, Arizona Electronic address
    Biol Blood Marrow Transplant 20:1375-81. 2014
    ..Future research should investigate potential interventions to help at-risk patients and prevent adverse financial outcomes after this life-saving procedure. ..
  2. pmc Costs of allogeneic hematopoietic cell transplantation using reduced intensity conditioning regimens
    Nandita Khera
    Division of Hematology Oncology, Mayo Clinic in Arizona, Phoenix, Arizona, USA Dana Farber Brigham and Women s Cancer Center, Boston, Massachusetts, USA Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    Oncologist 19:639-44. 2014
    ..Use of unrelated/alternative donors, transplant for diseases other than lymphoma or myeloma, and acute GVHD were predictors for higher early costs, and extensive chronic GVHD and death were associated with higher late costs. ..
  3. pmc Costs of second allogeneic hematopoietic cell transplantation
    Nandita Khera
    Division of Hematology Oncology, Mayo Clinic in Arizona, Phoenix, AZ, USA
    Transplantation 96:108-15. 2013
    ....
  4. pmc Nonmalignant late effects and compromised functional status in survivors of hematopoietic cell transplantation
    Nandita Khera
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    J Clin Oncol 30:71-7. 2012
    ..Our objective was to describe the incidence of nonmalignant late complications and their association with health and functional status in a recent cohort of hematopoietic cell transplantation (HCT) survivors...
  5. ncbi request reprint Economics of hematopoietic cell transplantation
    Nandita Khera
    Division of Hematology Oncology, Mayo Clinic Arizona, Phoenix, AZ, USA
    Blood 120:1545-51. 2012
    ..We discuss the need for more value-based assessments of HCT using high-quality approaches to measuring costs and outcomes so that potential future efforts to contain costs are well informed and appropriate...
  6. pmc Influence of conventional cardiovascular risk factors and lifestyle characteristics on cardiovascular disease after hematopoietic cell transplantation
    Eric J Chow
    Eric J Chow, K Scott Baker, Stephanie J Lee, Mary E D Flowers, Kara L Cushing Haugen, Yoshihiro Inamoto, Wendy M Leisenring, Karen L Syrjala, and Paul J Martin, Fred Hutchinson Cancer Research Center Eric J Chow, K Scott Baker, Seattle Children s Hospital Eric J Chow, K Scott Baker, Stephanie J Lee, Mary E D Flowers, and Paul J Martin, University of Washington, Seattle, WA and Nandita Khera, Mayo Clinic, Phoenix, AZ
    J Clin Oncol 32:191-8. 2014
    ..To determine the influence of modifiable lifestyle factors on the risk of cardiovascular disease after hematopoietic cell transplantation (HCT)...
  7. pmc Clinical benefit of response in chronic graft-versus-host disease
    Yoshihiro Inamoto
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington Electronic address
    Biol Blood Marrow Transplant 18:1517-24. 2012
    ..Modification of the algorithm or validation of other more meaningful clinical endpoints is warranted for future clinical trials of treatment for chronic graft-versus-host disease...
  8. ncbi request reprint Impact of Age on Quality of Life, Functional Status, and Survival in Patients with Chronic Graft-versus-Host Disease
    Areej El-Jawahri
    Division of Bone Marrow Transplantation, Massachusetts General Hospital Cancer Center, Boston, Massachusetts Harvard Medical School, Boston, Massachusetts Electronic address
    Biol Blood Marrow Transplant 20:1341-8. 2014
    ..Therefore, we did not find evidence that older age is associated with worse outcomes in patients with moderate or severe chronic GVHD. ..
  9. ncbi request reprint Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte ant
    James L Slack
    Division of Hematology and Oncology, Mayo Clinic Arizona, Phoenix, AZ 85054, USA
    Biol Blood Marrow Transplant 19:1167-74. 2013
    ..We conclude that FBM-A is an effective and safe conditioning regimen for adults up to age 69 with hematologic malignancies who have low-, intermediate-, or high-risk scores according to the DRI. ..
  10. pmc Validation of measurement scales in ocular graft-versus-host disease
    Yoshihiro Inamoto
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Ophthalmology 119:487-93. 2012
    ..Candidate scales were recommended for use in clinical trials by the National Institutes of Health (NIH) Chronic GVHD Consensus Conference or have been previously validated in dry eye syndromes...
  11. pmc Factors associated with adherence to preventive care practices among hematopoietic cell transplantation survivors
    Nandita Khera
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Biol Blood Marrow Transplant 17:995-1003. 2011
    ..Future efforts to improve adherence should address concerns about medical costs and lack of knowledge, two major modifiable predictors of lower adherence to preventive care practices in HCT survivors...
  12. pmc Limiting the daily total nucleated cell dose of cryopreserved peripheral blood stem cell products for autologous transplantation improves infusion-related safety with no adverse impact on hematopoietic engraftment
    Nandita Khera
    Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave North, Seattle, WA 98109, USA
    Biol Blood Marrow Transplant 18:220-8. 2012
    ..We conclude that limiting the daily TNC dose improved the safety of this procedure without compromising engraftment or increasing the costs of the procedure...